A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.
about
Aminosalicylates for induction of remission or response in Crohn's diseaseA dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseAminosalicylates for induction of remission or response in Crohn's diseasePlacebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn’s diseasePharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsMurine models of inflammatory bowel disease (IBD): challenges of modeling human diseaseEvolving Concepts in Phases I and II Drug Development for Crohn's Disease.Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.The placebo effect: illness and interpersonal healing.Clinical and genetic factors predicting response to therapy in patients with Crohn's disease.Are adult patients more tolerant of treatment risks than parents of juvenile patients?A randomized controlled trial of growth hormone in active pediatric Crohn disease.Placebo responses in patients with gastrointestinal disordersThe placebo effect in irritable bowel syndrome trials: a meta-analysis.Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's diseaseEuropean evidence based consensus on the diagnosis and management of Crohn's disease: current management.Placebo response in the prophylaxis of migraine: a meta-analysis.How to Review a Meta-analysisNew biologics in the management of Crohn's disease: focus on certolizumab pegol.Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysisCrohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trialsMeta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease.Age and sex as moderators of the placebo response – an evaluation of systematic reviews and meta-analyses across medicineMucosal healing in inflammatory bowel disease-a true paradigm of success?Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's diseasePhase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.Restraint stress induces and exacerbates intestinal inflammation in interleukin-10 deficient mice.The placebo response in functional bowel disorders: perspectives and putative mechanisms.Design issues and outcomes in IBD clinical trials.State of the art: IBD therapy and clinical trials in IBD.European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosisOutcomes of placebo therapy in inflammatory bowel disease.A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome.What predicts mucosal inflammation in Crohn's disease patients?Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870).Expanding role of capsule endoscopy in inflammatory bowel diseaseCertolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.Investigational agents for Crohn's disease.Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
P2860
Q24235730-28C4648A-65D4-460A-9F63-7FDFA61CEA36Q24680126-A3DBD3FD-5053-413F-8892-E75E0FF17FD7Q26471183-929560F3-21A3-458B-9FAC-1B06DC6B1F2FQ26471222-B22AA08C-0F5B-4A03-973E-0387E84215EAQ26768280-1E10CD40-59CE-4C43-A1A3-1D3565F0C5C9Q26863622-66BA230B-D8F9-432B-808A-03116A6658CDQ30248641-EBA13873-B84A-46EA-BB4D-28D8307DCF8EQ30440147-375A1410-9951-45E5-A69B-5C55B09E1B0AQ33621740-DC371DB6-6D53-4753-8D01-0377530CC575Q33695605-79CDB329-1A79-4286-8865-5CC9F0082400Q33761151-F73AD508-3835-4365-B0CC-25505951F4E6Q34023206-C6A1A1DC-A989-4ED3-997C-A4E862A4D59CQ34098616-97E553F2-4856-4F34-B902-5117824F72FBQ34421382-97DE7B01-2894-43AE-A68C-75A87E62210FQ34449843-291D59FB-D392-49F8-BB89-1D38D8263C1FQ34564902-7037F229-6868-494B-81BE-13A7F42AC998Q34621702-A9446CB2-F1AC-4583-9D46-B4B48A4ED224Q34996708-ECBA5B7D-BF7E-45B6-8798-8A80EBB6095CQ35026264-313AB51C-2494-4CAF-93D7-B625B7ED5F29Q35052356-478013C8-C5AB-44DE-AF0F-D73EF65FDD8BQ35055957-88A9B094-D82B-4D0A-BC4D-6568A286179BQ35098246-E8C2D385-B8F6-491A-8D64-55A81FF00D2BQ35147233-672A3411-C390-4DE8-8251-9A4102FBB30BQ35513153-E7884F7B-9E89-4540-825C-289CDBD62062Q35749943-A349D43C-669B-4B59-923F-453648BD888BQ35760252-7135A24E-4DF3-49CE-87B3-F1649C147D1AQ35876184-CA5560F6-B658-456F-8108-20C71E4A48A2Q35891396-0766495D-F7B4-4617-B13E-1504CC2E91B2Q36139392-40AEAD46-115C-4CD2-AFCE-5086D64DE749Q36299315-09494376-9B5A-4CE7-ACF7-D36B521F1973Q36299319-CE7D516B-2A58-453E-AB9F-A37DA13C26D6Q36397893-005CBEAE-D643-4141-A378-8A7ABFBBBB8DQ36457551-8DF78F81-E093-4A72-954E-BB5F3CD893FDQ36886282-B86DE99B-307C-4AAC-AB9A-0790C4732051Q36896566-5FDCD846-55C9-405F-B95D-6EE4D3521CECQ36920423-1690542D-9CAE-4E4B-9840-DE2541DC9046Q37219676-219D17F9-9B7C-403A-9799-17B3C3909F75Q37684572-B2E2EF3D-97A6-47A9-BC42-881AFB051C8FQ37788217-171ED23C-01F2-4AAE-9791-69219FC417E6Q37789693-DE44E881-D2F8-4B88-8507-92557844EFE7
P2860
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A meta-analysis of the placebo ...... als of active Crohn's disease.
@ast
A meta-analysis of the placebo ...... als of active Crohn's disease.
@en
A meta-analysis of the placebo ...... als of active Crohn's disease.
@nl
type
label
A meta-analysis of the placebo ...... als of active Crohn's disease.
@ast
A meta-analysis of the placebo ...... als of active Crohn's disease.
@en
A meta-analysis of the placebo ...... als of active Crohn's disease.
@nl
prefLabel
A meta-analysis of the placebo ...... als of active Crohn's disease.
@ast
A meta-analysis of the placebo ...... als of active Crohn's disease.
@en
A meta-analysis of the placebo ...... als of active Crohn's disease.
@nl
P2093
P1433
P1476
A meta-analysis of the placebo ...... als of active Crohn's disease.
@en
P2093
Colleen M Brensinger
Gary R Lichtenstein
James D Lewis
Karen Krok
P304
P356
10.1053/J.GASTRO.2004.01.024
P407
P577
2004-05-01T00:00:00Z